Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion

Introduction: In‐vivo quantification of serotonin transporters (SERT) in human brain has been a mainstay of molecular imaging in the field of neuropsychiatric disorders and helped to explore the underpinnings of several medical conditions, therapeutic and environmental influences. The emergence of PET/MR hybrid systems and the heterogeneity of SERT binding call for the development of efficient methods making the investigation of larger or vulnerable populations with limited scanner time and simultaneous changes in molecular and functional measures possible. We propose [11C]DASB bolus plus constant infusion for these applications and validate it against standard analyses of dynamic PET data. Methods: [11C]DASB bolus/infusion optimization was performed on data acquired after [11C]DASB bolus in 8 healthy subjects. Subsequently, 16 subjects underwent one scan using [11C]DASB bolus plus constant infusion with Kbol 160–179 min and one scan after [11C]DASB bolus for inter‐method reliability analysis. Arterial blood sampling and metabolite analysis were performed for all scans. Distribution volumes (VT) were obtained using Logan plots for bolus scans and ratios between tissue and plasma parent activity for bolus plus infusion scans for different time spans of the scan (VT‐70 for 60–70 min after start of tracer infusion, VT‐90 for 75–90 min, VT‐120 for 100–120 min) in 9 subjects. Omitting blood data, binding potentials (BPND) obtained using multilinear reference tissue modeling (MRTM2) and cerebellar gray matter as reference region were compared in 11 subjects. Results: A Kbol of 160 min was observed to be optimal for rapid equilibration in thalamus and striatum. VT‐70 showed good intraclass correlation coefficients (ICCs) of 0.61–0.70 for thalamus, striatal regions and olfactory cortex with bias ≤5.1% compared to bolus scans. ICCs increased to 0.72–0.78 for VT‐90 and 0.77–0.93 for VT‐120 in these regions. BPND‐90 had negligible bias ≤2.5%, low variability ≤7.9% and ICCs of 0.74–0.87; BPND‐120 had ICCs of 0.73–0.90. Low‐binding cortical regions and cerebellar gray matter showed a positive bias of ˜8% and ICCs 0.57–0.68 at VT‐90. Cortical BPND suffered from high variability and bias, best results were obtained for olfactory cortex and anterior cingulate cortex with ICC=0.74–0.75 for BPND‐90. High‐density regions amygdala and midbrain had a negative bias of −5.5% and −22.5% at VT‐90 with ICC 0.70 and 0.63, respectively. Conclusions: We have optimized the equilibrium method with [11C]DASB bolus plus constant infusion and demonstrated good inter‐method reliability with accepted standard methods and for SERT quantification using both VT and BPND in a range of different brain regions. With as little as 10–15 min of scanning valid estimates of SERT VT and BPND in thalamus, amygdala, striatal and high‐binding cortical regions could be obtained. Blood sampling seems vital for valid quantification of SERT in low‐binding cortical regions. These methods allow the investigation of up to three subjects with a single radiosynthesis. HighlightsSERT binding potentials in 15 min of scan time using [11C]DASB bolus + infusion.Reliability was compared to gold‐standard tracer bolus and arterial blood sampling.High reliability of BP in thalamus and striatal regions with ICCs 0.73–0.90.A protocol for SERT quantification in up to 3 patients with one radiosynthesis.

[1]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  S. Houle,et al.  Novel Radiotracers for Imaging the Serotonin Transporter by Positron Emission Tomography: Synthesis, Radiosynthesis, and in Vitro and ex Vivo Evaluation of (11)C-Labeled 2-(Phenylthio)araalkylamines. , 2000, Journal of medicinal chemistry.

[3]  Masanori Ichise,et al.  PET imaging of serotonin transporters with [11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Rupert Lanzenberger,et al.  Meta-analysis of molecular imaging of serotonin transporters in major depression , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  F. Larsen,et al.  The Pharmacokinetics of Escitalopram After Oral and Intravenous Administration of Single and Multiple Doses to Healthy Subjects , 2005, Journal of clinical pharmacology.

[6]  Linda Carpenter,et al.  Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography , 1998, Biological Psychiatry.

[7]  Rupert Lanzenberger,et al.  Quantification of Task-Specific Glucose Metabolism with Constant Infusion of 18F-FDG , 2016, The Journal of Nuclear Medicine.

[8]  R. Albin,et al.  Spared Caudal Brainstem SERT Binding in Early Parkinson's Disease , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  N. Filippini,et al.  Reduced Resting-State Functional Connectivity in Current and Recovered Restrictive Anorexia Nervosa , 2017, Front. Psychiatry.

[10]  Paul Cumming,et al.  PET Neuroimaging: The White Elephant Packs His Trunk? , 2014, NeuroImage.

[11]  C. Halldin,et al.  Pet study of [11C] β‐CIT binding to monoamine transporters in the monkey and human brain , 1994, Synapse.

[12]  R Dudczak,et al.  Simple and rapid preparation of [11C]DASB with high quality and reliability for routine applications. , 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[13]  J. Darcourt,et al.  Association of central serotonin transporter availability and body mass index in healthy Europeans , 2014, European Neuropsychopharmacology.

[14]  Claus Svarer,et al.  Seasonal difference in brain serotonin transporter binding predicts symptom severity in patients with seasonal affective disorder. , 2016, Brain : a journal of neurology.

[15]  Siegfried Kasper,et al.  Reduced resting-state functional connectivity between amygdala and orbitofrontal cortex in social anxiety disorder , 2011, NeuroImage.

[16]  Marc Laruelle,et al.  SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates , 1993, Synapse.

[17]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[18]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  Hank F Kung,et al.  Mass effect of injected dose in small rodent imaging by SPECT and PET. , 2005, Nuclear medicine and biology.

[20]  N. Lassen,et al.  Neuroreceptor Quantitation in vivo by the Steady-State Principle Using Constant Infusion or Bolus Injection of Radioactive Tracers , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  Pia Baldinger,et al.  Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression , 2014, Human brain mapping.

[22]  Christian Windischberger,et al.  (S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling , 2015, NeuroImage.

[23]  R. Albin,et al.  Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease. , 2012, Archives of neurology.

[24]  Pia Baldinger,et al.  Serotonin-1A receptor binding is positively associated with gray matter volume — A multimodal neuroimaging study combining PET and structural MRI , 2012, NeuroImage.

[25]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  S. Kasper,et al.  The serotonin transporter in psychiatric disorders: insights from PET imaging. , 2015, The lancet. Psychiatry.

[27]  Simon Cervenka,et al.  Diurnal and seasonal variation of the brain serotonin system in healthy male subjects , 2015, NeuroImage.

[28]  Mark Slifstein,et al.  The nature of dopamine dysfunction in schizophrenia and what this means for treatment. , 2012, Archives of general psychiatry.

[29]  J. Liow,et al.  Biodistribution and radiation dosimetry of the serotonin transporter ligand 11C-DASB determined from human whole-body PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  S. Houle,et al.  Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. , 2000, Journal of medicinal chemistry.

[31]  Sylvain Houle,et al.  Seasonal variation in human brain serotonin transporter binding. , 2008, Archives of general psychiatry.

[32]  Pia Baldinger,et al.  High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People , 2015, Biological Psychiatry.

[33]  Bruce R. Rosen,et al.  A receptor-based model for dopamine-induced fMRI signal , 2013, NeuroImage.

[34]  Siegfried Kasper,et al.  Normative database of the serotonergic system in healthy subjects using multi-tracer PET , 2012, NeuroImage.

[35]  Christer Halldin,et al.  Measurement of Striatal and Extrastriatal Dopamine D1 Receptor Binding Potential With [11C]NNC 112 in Humans: Validation and Reproducibility , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  Siegfried Kasper,et al.  Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas , 2012, NeuroImage.

[37]  Impact of flexible body surface coil and patient table on PET quantification and image quality in integrated PET/MR. , 2014, Nuklearmedizin. Nuclear medicine.

[38]  Alan A. Wilson,et al.  Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  Jeih-San Liow,et al.  Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  R. Chervin,et al.  The Role of Serotonin in Sleep Disordered Breathing Associated with Parkinson Disease: A Correlative [11C]DASB PET Imaging Study , 2012, PloS one.